Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 22 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Hydration Status
Interventions: Exercise; Other
Lead sponsor: PepsiCo Global R&D; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Frisco, Texas • Plano, Texas

Conditions: Juvenile Psoriatic Arthritis
Interventions: Adalimumab, Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 12
States / cities: Little Rock, Arkansas • Washington D.C., District of Columbia • Hollywood, Florida + 8 more

Conditions: Hematopoietic Stem Cell Transplantation
Interventions: Work Support (WorkS); Behavioral
Lead sponsor: MGH Institute of Health Professions; Other
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumors
Interventions: ADRX-0405; Drug
Lead sponsor: Adcentrx Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 8
States / cities: Duarte, California • Santa Monica, California • Grand Rapids, Michigan + 5 more

Conditions: Cervical Deformity
Interventions: Surgical intervention; Procedure
Lead sponsor: International Spine Study Group Foundation; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 16
States / cities: La Jolla, California • Sacramento, California • San Francisco, California + 11 more

Conditions: Peripheral Arterial Disease
Interventions: Ewing Below Knee Amputation, Standard Below Knee Amputation; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Decatur, Georgia • Nashville, Tennessee • Houston, Texas

Conditions: Neuropathy, Neuropathy;Peripheral
Interventions: Erchonia® EVRL™; Device
Lead sponsor: Erchonia Corporation; Industry
Eligibility: 22 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Bladder Cancer, Urinary Bladder Neoplasms
Interventions: MK-3120; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Bakersfield, California • New Brunswick, New Jersey • Myrtle Beach, South Carolina + 1 more

Conditions: Solid Tumor, Solid Tumor, Adult
Interventions: DESCANSO/Depresión/Depressed Mood, Cansancio/Fatigue, and Sueño/Sleep; Rest in English; Behavioral
Lead sponsor: Ponce Medical School Foundation, Inc.; Industry
Eligibility: 21 Years to 100 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Myasthenia Gravis
Interventions: Not listed
Lead sponsor: Vitaccess Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 6
States / cities: Orange, California • O'Fallon, Illinois • Lexington, Kentucky + 3 more

Conditions: Healthy Participants
Interventions: Lu AH69593, Itraconazole, Carbamazepine, Midazolam; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Quadriplegia
Interventions: Neural Communication System; Device
Lead sponsor: Richard A. Andersen, PhD; Other
Eligibility: 22 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2031
U.S. locations: 3
States / cities: Los Angeles, California • Pasadena, California • Pomona, California

Conditions: Enteric Hyperoxaluria
Interventions: Moderately High Oxalate (MOx) Diet; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Hematologic Neoplasms
Interventions: donor lymphocyte infusion, Cyclophosphamide, Busulfan, Mycophenolate mofetil, Fludarabine, Sirolimus; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity & Overweight
Interventions: Childcare; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 3 Years to 5 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Respiratory Distress Syndrome
Interventions: MIST surfactant; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: Up to 48 Hours
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Alpha-Thalassemia, Alpha Thalassemia Major, Alpha Thalassemia Minor
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2037
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Attention-deficit/Hyperactivity Disorder
Interventions: Methylphenidate Hydrochloride Extended Release Capsule; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Pelvic Metastasis
Interventions: Photodynamic nails; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Parents, Self Efficacy, Mental Health Literacy, Psychiatric Emergency
Interventions: iPEACE: Intervention for Parent Education about Care after the ED, Text Messaging Reminders Only; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Gulf War Syndrome, Gulf War Illness
Interventions: Not listed
Lead sponsor: Roskamp Institute Inc.; Other
Eligibility: 35 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Palo Alto, California • Sarasota, Florida • Boston, Massachusetts

Conditions: Fluid Output
Interventions: Electronic Device for Toilet; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Leukemia, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Lymphoblastic Lymphoma
Interventions: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide, Ofatumumab, Pegfilgrastim, Rituximab, Vincristine Sulfate Liposome; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)

Wearable Photoplethysmography for Non-invasive Hydration Assessment

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Employment Support After Hematopoietic Stem Cell Transplantation

A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors

Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity: A Multi-Center Study 2.0

Randomized Clinical Trial for Ewing Amputation in the VA

Clinical Efficacy of the Erchonia EVRL for Providing Temporary Relief of Idiopathic Peripheral Neuropathy Foot Pain

A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer

Vitaccess Real MG Registry

A Trial of Lu AH69593 in Healthy Participants

Visuomotor Prosthetic for Paralysis

Gut Kidney Axis in Enteric Hyperoxaluria

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Efficacy of Center-based Childcare to Mitigate Unhealthy Weight Gain in Preschoolers From Low-income Households During the Summer

Non Inferiority Trial Investigating Surfactants Administered Via MIST

International Registry of Patients With Alpha Thalassemia

An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening

Minimally-invasive Stabilization of Pelvic Metastases With Photodynamic Nails: A Multi-center Prospective Study of Functional Outcome

Text-messaging Intervention to Support Parents After Their Child's Psychiatric Emergency

Validating Gulf War Illness Blood Biomarkers

Testing a Device for Automatically TRacking Urine and STool in an Inpatient HCT Setting (Project TRUST)

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia